Results 31 to 40 of about 305 (130)

VALIDATION METHOD OF ULTRAVIOLET SPECTROPHOTOMETRY DETERMINATION OF CONTENT IN AMBROXOL HCl TABLET

Jurnal Natural, 2015
Ambroxol Hydrochloride (Ambroxol HCI) is one of mucolytic drugs that is commonly used to dilute thesecretion within the respiratory tract. This process is completed by lowering the viscosity of mucopolysaccharides, in which its characteristic which is ...
Tedy Kurniawan Bakri, Fathur Rahman Harun, Misrahanum ., Sadli .   +3 more
doaj   +2 more sources

Merger Efficiency and Coordinated Effects: Nothing to Sneeze at? Evidence From Cough and Cold Medicines in the Philippines

Southern Economic Journal, EarlyView.
ABSTRACT We investigate the competitive effects of a merger in the cough and cold medicines segment between GlaxoSmithKline (GSK) and Pfizer. The parties offered efficiency gains, and authorities concluded the merger would not lessen competition. Using product‐level data from the Philippines, we estimate a structural demand model to assess efficiency ...
Farasat A. S. Bokhari, Sean Ennis, Carlos Vega, Weijie Yan   +3 more
wiley   +1 more source

Efficacy and safety of inhaled ambroxol hydrochloride solution in patients with lower respiratory tract infectious diseases: a randomized, double-blind, placebo-controlled, multicentre clinical trial

BMC Infectious Diseases
Background Ambroxol is a widely used mucoactive agent, but the efficacy of inhaled ambroxol in patients with lower respiratory tract infectious (LRTI) disease is poorly understood.
Di Wu, Xiuhua Fu, Faguang Jin, Hui Li, Zhiqiang Qin, Haoyan Wang, Hongmei Yue, Jie Zhang, Zhaolong Cao   +8 more
doaj   +1 more source

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease

Molecular Genetics and Metabolism Reports, 2019
Type 3 Gaucher disease (GD3) is characterized by progressive neurological features in addition to the typical systemic manifestations. Enzyme replacement therapy (ERT), the main stay treatment for Gaucher disease (GD), is not efficacious for the ...
Behshad Charkhand, Morris H. Scantlebury, Aya Narita, Ari Zimran, Walla Al-Hertani   +4 more
doaj   +1 more source

Guideline for Medication Management of Distressing Symptoms in Older Patients Receiving End‐of‐Life Palliative Care

Journal of Evidence-Based Medicine, EarlyView.
ABSTRACT Older patients receiving end‐of‐life palliative care often present with multiple geriatric syndromes, frailty, and comorbid symptom burden, resulting in a high risk of medication‐related harm. This guideline focuses on pharmacological management of distressing symptoms in older patients receiving end‐of‐life or hospice‐oriented palliative care,
Daiping Li, Yanwu Yang, Yan Zhang, Jirong Yue, Birong Dong, Meiling Ge, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University   +7 more
wiley   +1 more source

Efficacy of high-dose ambroxol for paraquat poisoning: A meta-analysis of randomized controlled trials

Journal of Research in Medical Sciences, 2020
Background: Paraquat (PQ) poisoning is characterized by rapidly progressive acute poisoning with high mortality and no specific antidote. Although some clinical studies have been conducted to investigate the benefits of high-dose ambroxol as an adjuvant ...
Junwu Wang, Wensu Yu, Na Wu, Elaine N Gitonga, Haitao Shen   +4 more
doaj   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 357-374, August 2026.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Development of a new ultra-high performance liquid chromatography - tandem mass spectrometry method for determination of ambroxol hydrochloride in serum with pharmacokinetic application [PDF]

Hemijska Industrija, 2016
Ambroxol hydrochloride is an expectorant agent, successfully applied in mucolytic therapy for acute and chronic bronchopulmonary diseases. The drug regulates not only mucus secretion but also showed antioxidant, anti-inflammatory and local ...
Vujović Maja M., Jokanović Milan, Nikolić Goran M.   +2 more
doaj   +1 more source

Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial

The Clinical Respiratory Journal, Volume 20, Issue 7, July 2026.
In this randomized, double‐blind, placebo‐controlled trial involving 160 children with mild Mycoplasma pneumoniae pneumonia, adding Lianhua Qingke tablets to conventional therapy significantly improved symptom resolution by Day 7 (85.9% vs. 65.6%) and shortened median recovery time (4.5 vs.
He Wang, Haiwei Dou, Guangying Chen, Yanmin Wei, Hua Li, Shuqiong Xu, Rongzhen Kang, Shanhong Liu, Long Zhang, Nan Li, Hongli Sun, Chi Wang, Jie Zhao, Jirong Yi, Wentao Song, Hongrong Li, Rong Ma, Kunling Shen, Deli Xin, Wenjie Qi   +19 more
wiley   +1 more source

Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation

BMC Microbiology
It is critical to find novel therapeutic approaches owing to the dissemination of multidrug resistance (MDR) in pathogenic bacteria, particularly Staphylococcus aureus. FDA-drug repurposing is an important therapeutic tactic to fight MDR bacteria.
Ahmed A. Abdelaziz, Amal M. Abo-Kamar, Alaa E. Ashour, Moataz A. Shaldam, Engy Elekhnawy   +4 more
doaj   +1 more source